Artiva Biotherapeutics, Inc. (ARTV)
2025-06-30 | 2025-03-31 | 2024-09-30 | 2024-06-30 | |
|---|---|---|---|---|
| Unrealized gain (loss) on investments, net | 2 | 129 | 217 | -86 |
| Research and development (including related party amounts of 27, 1,172, 50 and 1,459, respectively) | 17,861 | 17,052 | 13,524 | 12,333 |
| General and administrative | 4,949 | 5,119 | 4,811 | 3,857 |
| Total operating expenses | 22,810 | 22,171 | 18,335 | 16,190 |
| Loss from operations | -22,810 | -22,171 | -18,335 | -16,190 |
| Change in fair value of safes (including related party amounts of 2,911 and 0, respectively) | - | - | -977 | -2,352 |
| Other income (expense), net | -5 | -4 | -6 | 23 |
| Interest income | 1,561 | 1,864 | 1,846 | 676 |
| Total other income (expense), net | 1,556 | 1,860 | 863 | -1,653 |
| Net loss | -21,254 | -20,311 | -17,472 | -17,843 |
| Comprehensive loss | -21,252 | -20,182 | -17,255 | -17,929 |
| Earnings per share, basic | -0.87 | -0.83 | -0.92 | -22 |
| Earnings per share, diluted | -0.87 | -0.83 | -0.92 | -22 |
| Weighted average number of shares outstanding, basic | 24,378,823 | 24,341,978 | 18,896,829 | 811,210 |
| Weighted average number of shares outstanding, diluted | 24,378,823 | 24,341,978 | 18,896,829 | 811,210 |